Menopause Without HRT: Non-Hormonal Options, Risks, and What the Evidence Actually Shows

Why Some Women Choose to Avoid HRT

Hormone replacement therapy remains the most effective intervention for menopausal vasomotor symptoms, yet roughly half of eligible women either prefer to avoid it or have medical contraindications [1]. Contraindications include estrogen-receptor-positive breast cancer history, active or recent venous thromboembolism, unexplained vaginal bleeding, and certain liver diseases [2]. Personal preference, family history of hormone-sensitive cancers, or prior experience with side effects also drive the decision.

The 2002 Women's Health Initiative (WHI) primary publication frightened millions of women and clinicians alike, but subsequent reanalyses substantially refined the picture. The absolute excess risk of invasive breast cancer in the combined estrogen-progestogen arm was 8 additional cases per 10,000 women per year, a figure that varies considerably by age of initiation, formulation, and duration [3]. Women who start hormone therapy within 10 years of menopause and before age 60 show a more favorable risk-benefit ratio than those starting later, a concept now called the "timing hypothesis" [4].

That nuance matters because it shapes what "menopause without HRT" actually means. For women in their early 50s with moderate symptoms and no contraindications, choosing non-hormonal management is a preference decision supported by good alternatives. For women with active breast cancer, it is a medical necessity with a different risk calculus entirely.

Non-Hormonal Prescription Drugs with FDA-Level Evidence

Several prescription medications reduce vasomotor symptoms through mechanisms unrelated to estrogen. The evidence base for each differs in quality and effect size.

Fezolinetant (Veozah). The FDA approved fezolinetant in May 2023 as the first non-hormonal drug developed specifically for menopausal hot flashes [5]. It works by blocking the NK3 receptor in the hypothalamic thermoregulatory center, the same pathway activated by estrogen deficiency. In SKYLIGHT 1 (N=501), fezolinetant 45 mg daily reduced moderate-to-severe hot flash frequency by approximately 60% at week 12 compared with a 45% reduction in the placebo arm, with a statistically significant difference of P<0.001 [6]. The most common adverse events were abdominal pain and hepatic enzyme elevation, which resolved after discontinuation. Liver function monitoring is required at baseline and at 3, 6, and 9 months.

Paroxetine 7.5 mg (Brisdelle). This low-dose paroxetine formulation carries the only FDA approval among SSRIs and SNRIs specifically for vasomotor symptoms [7]. The approval was based on two Phase III trials showing a mean reduction of 5 to 6 hot flashes per day versus 3 to 4 with placebo at 12 weeks. Women taking tamoxifen for breast cancer should avoid paroxetine because it inhibits CYP2D6, reducing tamoxifen conversion to its active metabolite endoxifen by up to 65% [8].

Venlafaxine and other SNRIs. Off-label venlafaxine 37.5 to 75 mg daily produces a roughly 50 to 60% reduction in hot flash composite scores in clinical trials, comparable to lower estrogen doses in some head-to-head comparisons [9]. The North American Menopause Society (NAMS) 2023 position statement lists venlafaxine, desvenlafaxine, escitalopram, and citalopram as evidence-based off-label options [10].

Gabapentin. At doses of 900 to 2 to 400 mg per day in divided doses, gabapentin reduces hot flash frequency by roughly 45% [11]. Sedation and dizziness limit tolerability for many women, though the sedative effect can benefit those with significant sleep disruption.

Oxybutynin. Originally approved for overactive bladder, oxybutynin 2.5 to 5 mg twice daily showed a 73% reduction in hot flash frequency versus 29% placebo in a randomized trial by Leon-Ferre et al. (N=150) [12]. Dry mouth and cognitive effects are the primary concerns, particularly in women over 65.

[]

The table below summarizes how to sequence non-hormonal options based on comorbidities, a decision framework developed by the HealthRX clinical team for use in our patient intake protocol.

| Comorbidity or concern | Preferred first-line non-hormonal option | Avoid | |---|---|---| | Depression or anxiety | Venlafaxine or escitalopram | Oxybutynin | | On tamoxifen | Venlafaxine, gabapentin, or fezolinetant | Paroxetine | | Sleep disruption dominant | Gabapentin (evening dose) | Stimulating SNRIs AM dosing | | Overactive bladder + hot flashes | Oxybutynin | Gabapentin (worsens cognition) | | No comorbidities, hot flashes only | Fezolinetant 45 mg daily | None specific |

Behavioral and Lifestyle Strategies: What the Data Show

Lifestyle measures are frequently recommended first in primary care, but their effect sizes are modest and the trial quality is variable. Women should receive accurate expectations.

Cognitive behavioral therapy (CBT). The MENOS 1 randomized controlled trial (N=140) tested a 6-session group CBT program against a waitlist control in women with breast cancer-related hot flashes [13]. At 9-week follow-up, the CBT group reported a 50% reduction in problem rating (a composite of frequency and distress) versus 10% in controls. The MENOS 2 trial extended these findings to natural menopause and showed durable benefits at 6 months [14]. CBT does not reliably reduce the number of flashes measured by ambulatory monitoring, but it substantially reduces perceived bother, which is often the clinically relevant endpoint.

Weight loss. A secondary analysis of the PROBE trial found that women who lost at least 10 lbs over 6 months were significantly more likely to eliminate hot flashes entirely (odds ratio 1.65 to 95% CI 1.07 to 2.55) compared with women in the usual-care group [15]. Adipose tissue produces estrone, an estrogen metabolite, so weight loss may paradoxically worsen symptoms in some women by lowering estrone levels. Clinicians should monitor symptom response.

Aerobic exercise. A 2014 Cochrane review (six trials, N=732) found insufficient evidence that exercise reduces vasomotor symptoms compared with control conditions, though exercise improved mood, sleep quality, and quality-of-life scores [16]. Recommending exercise is reasonable for general health; setting expectations that it will eliminate hot flashes is not supported by current data.

Dietary changes. Phytoestrogen-rich diets and soy isoflavone supplements have been studied extensively. A 2020 meta-analysis in Menopause (45 trials) found soy isoflavones reduced hot flash frequency by a mean of 1.4 per day versus placebo, a statistically significant but clinically small difference for most women [17]. A diet rich in whole soy foods is low-risk and may help women with mild symptoms.

How Fast Does HRT Work When You Do Start?

For women who eventually decide to begin hormone therapy after a non-hormonal trial period, understanding the timeline helps with adherence and expectation-setting. Vasomotor symptom relief typically begins within 2 to 4 weeks of starting systemic estrogen, with maximum benefit at 8 to 12 weeks [18]. Sleep quality often improves before hot flash frequency fully normalizes, because lower nighttime core temperature occurs even before flash frequency drops to baseline.

Vaginal and genitourinary symptoms respond more slowly. Local estradiol (vaginal ring, cream, or tablet) takes 6 to 12 weeks for full mucosa restoration [19]. Bone density changes are detectable on DEXA at 12 months, not weeks [20].

Transdermal estradiol patches reach steady-state plasma levels in 3 to 4 days after application. Oral estradiol has first-pass hepatic metabolism that delays the full systemic effect slightly compared with transdermal routes, though the symptomatic onset difference is small in practice [21].

The specific estrogen dose matters for onset speed. Women starting at 0.025 mg/day transdermal estradiol (a low starter dose) may take longer to see relief than those initiated at 0.05 mg/day [22]. If no response appears at 8 weeks, dose adjustment rather than discontinuation is the appropriate clinical step, per the 2023 NAMS guidelines [10].

Can You Stop HRT Cold Turkey?

Stopping HRT abruptly is not medically dangerous in the way that stopping corticosteroids or beta-blockers can be. Serum estradiol falls to postmenopausal levels within 24 to 72 hours of patch removal or pill cessation, but there is no adrenal suppression or cardiac risk from the rate of drop itself [23].

The primary consequence of abrupt discontinuation is symptom rebound. Studies show that 50 to 80% of women experience return of hot flashes within weeks of stopping, often at pre-treatment severity or worse in the short term [24]. The 2023 Menopause Society statement notes that gradual dose tapering over 3 to 6 months is preferred over abrupt cessation to minimize rebound vasomotor symptoms, though it acknowledges that trial evidence directly comparing tapering schedules is limited [10].

A practical tapering protocol used in many practices: reduce the estradiol dose by one step every 4 to 8 weeks (for example, from 0.05 mg to 0.0375 mg patch, then to 0.025 mg, then to 0.014 mg before stopping). For oral estradiol 1 mg daily, moving to 0.5 mg for 8 weeks before stopping is a reasonable approach. Women on combined estrogen-progestogen should continue the progestogen at each dose level to maintain endometrial protection during the taper, then discontinue both together at the final step.

Some women need to stop quickly due to a new breast cancer diagnosis, planned surgery with high VTE risk, or another emergent indication. In those cases, stopping immediately is the correct clinical action despite the rebound risk, and symptom management shifts to non-hormonal options described above.

How Long Can You Stay on HRT?

No fixed maximum duration applies universally. The 2023 Menopause Society position statement states: "There is no arbitrary limit on the duration of hormone therapy use," provided that treatment is reviewed annually and benefits continue to outweigh risks for the individual patient [10]. This represents a significant departure from the post-WHI guidance of "the lowest dose for the shortest time" that dominated clinical practice from 2002 onward.

The nuances matter. Breast cancer risk with combined estrogen-progestogen therapy increases with duration of use. The Collaborative Group on Hormonal Factors in Breast Cancer (Collaborative reanalysis, N=108,647 women with breast cancer) found that current users of combined HRT had a relative risk of 1.60 (95% CI 1.52 to 1.69) compared with never-users, with risk rising with duration [25]. By contrast, estrogen-only therapy (appropriate for women after hysterectomy) showed a relative risk of 1.17 (95% CI 1.10 to 1.26), substantially lower [25].

The annual clinical review should assess ongoing symptom burden, the specific formulation (type of progestogen matters, with micronized progesterone showing lower breast-cancer signal than synthetic progestogens), cardiovascular risk changes, bone density results, and patient preference [26]. Women who remain symptomatic at age 65 should not be forced off therapy solely on the basis of age, according to the British Menopause Society guidelines [27]. The conversation about duration is individualized, not algorithmic.

For women using local vaginal estrogen only, duration concerns are minimal. Systemic absorption from vaginal estradiol 10 mcg tablets is negligible, and no upper duration limit is supported by the evidence [28].

HRT and Pregnancy: A Clinically Important Misunderstanding

HRT prescribed for menopausal symptoms does not provide contraception. Perimenopause, defined as the transition period before the final menstrual period, can last 4 to 8 years [29]. Ovulation remains possible during this window, even when cycles are irregular or infrequent.

Standard menopause HRT doses (for example, estradiol 0.05 mg/day transdermal plus micronized progesterone 100 to 200 mg/day) are far below the doses used in oral contraceptives and do not reliably suppress ovulation [30]. A woman who uses HRT during perimenopause without contraception therefore retains pregnancy risk until she has had 12 consecutive months of amenorrhea (the standard clinical definition of menopause) if she is over age 50, or 24 months if under 50 [29].

The recommended contraceptive options during perimenopause include low-dose combined oral contraceptive pills (also effective for symptom control and cycle regulation), levonorgestrel IUD, copper IUD, barrier methods, or sterilization [31]. The levonorgestrel IUD has the added benefit of serving as the progestogen component of an HRT regimen when systemic estrogen is added, a combination supported by NICE guideline NG23 [32].

Pregnancy during perimenopause carries substantially higher risks than pregnancy at younger ages: miscarriage rates exceed 50% for women over 45, and maternal rates of gestational diabetes, hypertensive disorders, and placental complications increase markedly [33]. Clinicians prescribing HRT to any woman who has not yet confirmed menopause should document a contraceptive plan.

After confirmed menopause, pregnancy is not biologically possible without donor egg IVF with exogenous hormonal support, a separate clinical context with its own protocols.

Genitourinary Syndrome of Menopause: The Symptom Most Undertreated Without HRT

Genitourinary syndrome of menopause (GSM) includes vaginal dryness, dyspareunia, recurrent urinary tract infections, and urinary urgency caused by urogenital tissue atrophy from estrogen deficiency. Unlike vasomotor symptoms, which resolve in most women within 5 to 7 years, GSM is progressive and does not improve without treatment [34].

Non-hormonal options for GSM include:

• Vaginal moisturizers (polycarbophil-based, used 3 times per week): reduce dryness scores by roughly 40% in randomized trials, comparable to vaginal estrogen in the REVIVE survey cohort but inferior in head-to-head RCTs [35].
• Ospemifene (Osphena): An oral selective estrogen receptor modulator approved by the FDA for dyspareunia from GSM at 60 mg daily [36]. Contraindicated in women with estrogen-receptor-positive breast cancer.
• Intrarosa (prasterone/DHEA vaginal insert): FDA-approved in 2016 for dyspareunia from GSM; 6.5 mg insert nightly; local conversion to estrogens and androgens in vaginal tissue with negligible systemic levels [37].

For women who cannot or choose not to use any estrogenic product, vaginal moisturizers and lubricants remain the only evidence-supported non-hormonal options, with modest but real benefit [35].

Bone and Cardiovascular Health Without HRT

Estrogen deficiency accelerates bone resorption. Women lose an average of 2% of lumbar spine bone density per year in the first 2 to 5 years after menopause [38]. For women who decline HRT, bone protection strategies include adequate calcium (1 to 200 mg per day from food and supplements combined for women over 50) and vitamin D (800 to 1 to 000 IU daily), combined with weight-bearing and resistance exercise [39]. DEXA screening at menopause onset and repeated at intervals based on baseline T-score allows monitoring [40].

For women with osteopenia (T-score between -1.0 and -2.5), the USPSTF recommends risk stratification using the FRAX tool before initiating pharmacological therapy [41]. Bisphosphonates (alendronate 70 mg weekly, risedronate 35 mg weekly) are first-line pharmacological options when fracture risk crosses the intervention threshold [42].

Cardiovascular risk rises after menopause partly from estrogen loss affecting lipid profiles and vascular function. For women managing menopause without HRT, standard cardiovascular risk reduction applies: smoking cessation, statin therapy when indicated, blood pressure control, and physical activity [43]. The 2021 ACC/AHA cardiovascular risk guidelines do not recommend HRT for primary cardiovascular prevention [44].